Expertise in
2
conditions

Clare J. Rowntree

Cardiff, WLS, GB 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
2
conditions
Cardiff, WLS, GB 

Overview

Clare Rowntree practices practicing medicine in Cardiff, United Kingdom.

Ms. Rowntree is highly rated in 2 conditions, according to our data. Her clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Leukemia, Non-Hodgkin Lymphoma, and B-Cell Lymphoma.

She is actively involved in clinical research, co-authoring 31 peer reviewed articles and participating in 2 clinical trials.

Gender

Female

Locations

Cardiff, WLS, United Kingdom
Other Locations
Bristol, ENG, United Kingdom
London, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

ALLTogether1 - A Treatment Study Protocol of the ALLTogether Consortium for Children and Young Adults (0-45 Years of Age) With Newly Diagnosed Acute Lymphoblastic Leukaemia (ALL)
ALLTogether1 - A Treatment Study Protocol of the ALLTogether Consortium for Children and Young Adults (0-45 Years of Age) With Newly Diagnosed Acute Lymphoblastic Leukaemia (ALL)
Enrollment Status: Recruiting
Publish Date: August 12, 2026
Intervention Type: Drug
Study Drugs: Doxorubicin, Vincristine, Dexamethasone, Inotuzumab, Imatinib, 6-Tioguanine, Blinatumomab
Study Phase: Phase 3
International Phase I/II Expansion Trial of the MEK Inhibitor Selumetinib in Combination With Dexamethasone for the Treatment of Relapsed/Refractory RAS-pathway Mutated Paediatric and Adult Acute Lymphoblastic Leukaemia
International Phase I/II Expansion Trial of the MEK Inhibitor Selumetinib in Combination With Dexamethasone for the Treatment of Relapsed/Refractory RAS-pathway Mutated Paediatric and Adult Acute Lymphoblastic Leukaemia
Enrollment Status: Terminated
Publish Date: May 11, 2023
Intervention Type: Drug
Study Drugs: Selumetinib, Dexamethasone
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

31 Total Publications

EARLY RESPONSE AND GENETICS DEFINE RELAPSE RISK AFTER FRONTLINE BLINATUMOMAB IN CHILDHOOD B-ALL: A COHORT STUDY.
EARLY RESPONSE AND GENETICS DEFINE RELAPSE RISK AFTER FRONTLINE BLINATUMOMAB IN CHILDHOOD B-ALL: A COHORT STUDY.
Journal: Blood advances
Published: May 07, 2026

Frequently Asked Questions about Clare J. Rowntree

Is Clare J. Rowntree a top-rated expert for Acute Lymphoblastic Leukemia (ALL)?

MediFind is an objective health platform that identifies experts based on real-world data. Clare J. Rowntree is classified as an Advanced expert for Acute Lymphoblastic Leukemia (ALL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Clare J. Rowntree participate in research or clinical trials?

Yes. Clare J. Rowntree has published 31 articles and abstracts on conditions like Acute Lymphoblastic Leukemia (ALL). You can view a list of Clare J. Rowntree's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Rowntree's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile